StockData
Protara Therapeutics, Inc. logo

Protara Therapeutics, Inc. (TARA) stock

TARANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 7/30
$2.32−0.06 (-2.52%)

Close on Nov 17, 2026Market cap $137.10MP/E –Yield –

Protara Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Protara Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $53.23M, up 42.0% year over year. For fiscal 2025 it was $42.63M, up 34.5% from the year before. Over ten years it grew 13.2% a year on average. The highest annual figure on record is $42.63M in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$42.63M+34.5%
FY2024Dec 31, 2024$31.70M+26.9%
FY2023Dec 31, 2023$24.99M+48.7%
FY2022Dec 31, 2022$16.81M-20.3%
FY2021Dec 31, 2021$21.09M+76.0%
FY2020Dec 31, 2020$11.98M+209.0%
FY2019Dec 31, 2019$3.88M-67.3%
FY2018Dec 31, 2018$11.85M-45.4%
FY2017Dec 31, 2017$21.69M+14.9%
FY2016Dec 31, 2016$18.87M+52.4%
FY2015Dec 31, 2015$12.38M+92.5%
FY2014Dec 31, 2014$6.43M+61.0%
FY2013Dec 31, 2013$3.99M-32.4%
FY2012Dec 31, 2012$5.91M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$16.96M+57.4%
Q1 FY2026Mar 31, 2026$13.56M+48.3%
Q4 FY2025Dec 31, 2025$13.12M+38.2%
Q3 FY2025Sep 30, 2025$9.59M+18.8%
Q2 FY2025Jun 30, 2025$10.77M+68.6%
Q1 FY2025Mar 31, 2025$9.15M+18.1%
Q4 FY2024Dec 31, 2024$9.50M+48.9%
Q3 FY2024Sep 30, 2024$8.07M+29.8%
Q2 FY2024Jun 30, 2024$6.39M-11.9%
Q1 FY2024Mar 31, 2024$7.75M+50.7%
Q4 FY2023Dec 31, 2023$6.38M+27.9%
Q3 FY2023Sep 30, 2023$6.22M+79.4%
Q2 FY2023Jun 30, 2023$7.25M+135.0%
Q1 FY2023Mar 31, 2023$5.14M-2.4%
Q4 FY2022Dec 31, 2022$4.99M+22.6%
Q3 FY2022Sep 30, 2022$3.47M-15.3%
Q2 FY2022Jun 30, 2022$3.08M-47.6%
Q1 FY2022Mar 31, 2022$5.27M-25.2%
Q4 FY2021Dec 31, 2021$4.07M+11.4%
Q3 FY2021Sep 30, 2021$4.09M+46.4%
Q2 FY2021Jun 30, 2021$5.89M+138.3%
Q1 FY2021Mar 31, 2021$7.04M+129.7%
Q4 FY2020Dec 31, 2020$3.65M+410.9%
Q3 FY2020Sep 30, 2020$2.80M+154.5%
Q2 FY2020Jun 30, 2020$2.47M+150.3%
Q1 FY2020Mar 31, 2020$3.07M+184.4%
Q4 FY2019Dec 31, 2019$714.82K-73.2%
Q3 FY2019Sep 30, 2019$1.10M-53.3%
Q2 FY2019Jun 30, 2019$986.72K-64.2%
Q1 FY2019Mar 31, 2019$1.08M-73.5%
Q4 FY2018Dec 31, 2018$2.66M-17.1%
Q3 FY2018Sep 30, 2018$2.35M-77.2%
Q2 FY2018Jun 30, 2018$2.76M-29.1%
Q1 FY2018Mar 31, 2018$4.07M-4.1%
Q4 FY2017Dec 31, 2017$3.21M-27.6%
Q3 FY2017Sep 30, 2017$10.34M+113.5%
Q2 FY2017Jun 30, 2017$3.89M–
Q1 FY2017Mar 31, 2017$4.25M–
Q4 FY2016Dec 31, 2016$4.44M–
Q3 FY2016Sep 30, 2016$4.84M–

More Protara Therapeutics figures

See a number that looks wrong?